RESUMO
Polymannuronic acid (PM) is an alginate oligosaccharide derived from brown algae with a characterized structure and excellent biological activities. Herein, mice were given different doses of PM through 30-day-long-term intragastric administration, and the contents of the jejunum, ileum, and colon were analyzed by 16S rRNA gene sequencing technology for microbial diversity, and relevant experiments were verified according to the analysis results so as to comprehensively evaluate the effects of PM on the intestinal flora. The PM (400 mg/kg and 100 mg/kg) could regulate the microflora balance at the phylum level and increase the microflora richness in the jejunum, ileum, and colon of the mice. The PM could induce more strains that are negatively correlated with Escherichia, thereby reducing the relative abundance of Escherichia. Analysis of bacterial function showed that high and low doses of PM could promote lipid metabolism in the bacterial communities. Moreover, the PM could reduce serum total cholesterol and cholesterol ester levels in a concentration-dependent manner. High-dose PM could lead to colonic intestinal inflammation by increasing the relative abundance of multiple bacterial groups in the jejunum, ileum, and colon. Moreover, high-dose PM could increase lipopolysaccharide-binding protein and interleukin-1ß levels. Therefore, the dose of PM plays an important role in its efficacy, and its biological activity is dosedifferent.
Assuntos
Ácido Algínico , Microbioma Gastrointestinal , Animais , Camundongos , RNA Ribossômico 16S , Alginatos , ÍleoRESUMO
Malignant tumors contribute significantly to human mortality. Chemotherapy is a commonly used treatment for tumors. However, due to the low selectivity of chemotherapeutic drugs, immune cells can be damaged during antitumor treatment, resulting in toxicity. Lipopolysaccharide (LPS) can stimulate immune cells to respond to foreign substances. Here, we found that 10â¯ng/mL LPS could induce tolerance to antitumor drugs in macrophages without altering the effect of the drugs on tumor cells. Differentially expressed genes (DEGs) were identified between cells before and after LPS administration using transcriptome sequencing and found to be mainly associated with ATP-binding cassette (ABC)-resistant transporters and glutathione S-transferase (GST). LPS was shown by qRT-PCR and western blotting to promote the expression of ABCC1, GSTT1, and GSTP1 by 38.3â¯%, 194.8â¯%, and 27.0â¯%. Furthermore, three inhibitors (inhibitors of GST, glutathione synthesis, and ABCC1) were used for further investigation, showing that these inhibitors reduced macrophage survival rates by 44.0â¯%, 52.3â¯%, and 43.3â¯%, while the intracellular adriamycin content increased by 28.9â¯%, 42.9â¯%, and 51.3â¯%, respectively. These findings suggest that the protective mechanism of LPS on macrophages is associated with increased GST activity, the consumption of glutathione, and increased expression of ABCC1 protein. Therefore, LPS has a potential role in enhancing immunity.
Assuntos
Lipopolissacarídeos , Macrófagos , Proteínas Associadas à Resistência a Múltiplos Medicamentos , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Macrófagos/imunologia , Camundongos , Animais , Proteínas Associadas à Resistência a Múltiplos Medicamentos/metabolismo , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Antineoplásicos/farmacologia , Doxorrubicina/farmacologia , Glutationa Transferase/metabolismo , Glutationa Transferase/genética , Células RAW 264.7 , Humanos , Glutationa/metabolismo , Glutationa S-Transferase pi/genética , Glutationa S-Transferase pi/metabolismo , Sobrevivência Celular/efeitos dos fármacosRESUMO
Atherosclerosis (AS) is the common basis for the onset of cardiovascular events. The lipid metabolism theory considers foam cell formation as an important marker for the initiation of AS. Fucoidan is an acidic polysaccharide that can reduce lipid accumulation in foam cells. Studies show that tea polysaccharides can be transported to lysosomes via the tubulin pathway. However, the specific mechanism of action of fucoidan on foam cells has not been extensively studied. Therefore, we further explored the mechanism of action of fucoidan and evaluated whether it could reduce lipid accumulation in foam cells by affecting the expression of lysosomal pathway-related genes and proteins. In this study, three inhibitors, CPZ, EIPA, and colchicine, were used to inhibit endocytosis, macropinocytosis, and the tubulin pathway, respectively, to study the pathways of action. Transcriptomics and proteomics analysis, as well as western blotting and qRT-PCR were used to determine the effects of fucoidan and the inhibitors on lysosomal genes and proteins. Fucoidan could enter foam cells through both endocytosis and via macropinocytosis, and then further undergo intracellular transport via the tubulin pathway. After fucoidan treatment, the expression of lysosomal pathway-related genes and proteins including LAMP2, AP3, AP4, MCOLN1, and TFEB in foam cells increased significantly (P < 0.01). However, the expression of lysosomal genes and proteins after colchicine intervention was comparable with that in the model group. Therefore, the tubulin pathway inhibited by colchicine is an important pathway for the transport and distribution of fucoidan within cells. In summary, fucoidan may be transported to lysosomes via the tubulin pathway and may enhance the expression of lysosomal genes, promoting autophagy, thereby accelerating lipid clearance in foam cells. Due to its significant lipid-lowering effect, it can be used in the clinical treatment of AS.
Assuntos
Aterosclerose , Células Espumosas , Humanos , Células Espumosas/metabolismo , Tubulina (Proteína)/metabolismo , Aterosclerose/tratamento farmacológico , Polissacarídeos/uso terapêutico , Lipídeos/farmacologia , Lisossomos/metabolismo , Colchicina/metabolismoRESUMO
Polyguluronic acid (PG), a polysaccharide from alginate, possesses excellent bioactivities. We prepared high-purity PG with 10.41 kDa molecular weight (Mw) and a 59 average degree of polymerization (DP) by acid hydrolysis, three pH grades, Q-Sepharose column elution, and Sephadex G-25 column desalination. Then, we evaluated the PG protective effects on doxorubicin-induced cardiotoxicity (DIC) in vitro and in vivo. The nontoxic PG enhanced cellular viability, reduced cell pyroptosis morphology, diminished the LDH and IL-1ß release, and downregulated expressions of ASC oligomerization, NLRP3, cl-CASP1, and GSDMD, by which PG protected the cardiomyocytes from NLRP3 inflammasome-mediated pyroptosis in doxorubicin-stimulated HL-1 cells and C57BL/6J mice. The probable underlying mechanism may be that PG downregulated doxorubicin -induced Peli1, the deficiency of which could inhibit doxorubicin-induced NLRP3 inflammasome-mediated pyroptosis. These results suggested that polysaccharide PG from alginate could prevent DIC and may be a potential therapeutic agent or bioactive material for preventing DIC.
Assuntos
Inflamassomos , Piroptose , Camundongos , Animais , Camundongos Endogâmicos C57BL , Proteína 3 que Contém Domínio de Pirina da Família NLR , Cardiotoxicidade/tratamento farmacológico , Alginatos/farmacologia , Doxorrubicina/toxicidade , Proteínas Nucleares , Ubiquitina-Proteína LigasesRESUMO
Building stimulus-responsive units in the hydrogel coatings remains challenging for film sensors consisting of alternated layers of inert substrates and hydrogel coatings. An interesting film sensor with a carboxymethyl starch-based hydrogel coating was developed here. The cross-linking networks of carboxymethyl starch play the roles of structure-constructing units and stimulus-controlling units simultaneously, endowing the coatings with thermal sensing and strain sensing capabilities. The dynamic cross-links formed via the boronic ester bonds are temperature-sensitive, releasing or consuming additional acid ions with temperature alteration, and also as primary networks give the hydrogel strength and stretchability with the assistance of semi-penetrated polyacrylamide chains. Therefore, as-prepared flexible film sensors can be used to detect the periodic changes of human temperature and small-scale motion with multiple working modes, discriminating the physical states related to human health. Moreover, this kind of starch-based coating is degradable in a strongly alkaline solution and the inert substrate layer can protect the skin from erosion caused by direct hydrogel-skin contact, and thereby the film sensor is human- and environmentally friendly. This work also proposes a strategy of building temperature-sensitive units in the film sensor via regulating the chemical networks, instead of tuning physical structures.
RESUMO
ETHNOPHARMACOLOGICAL RELEVANCE: The incidence of atherosclerotic cardiovascular disease is a serious threat to human health. Leeches are used in traditional Chinese medicine to treat cardiovascular diseases. HE-D is an active peptide extracted and isolated from leeches, which can inhibit the migration of RAW264.7 macrophages. AIM: This study shows the effects of HE-D on macrophages in atherosclerosis and the mechanism of inhibition on the migration of macrophages based on transcriptome sequencing (RNA-Seq). MATERIALS AND METHODS: The transwell method was used to detect the activity of HE-D in inhibiting the migration of macrophages. Macrophages were divided into control group, lipopolysaccharide group, and HE-D group. Samples were collected and RNA-Seq performed. The DEseq2 method detected significantly differentially expressed genes (DEGs), GO and KEGG Pathway databases were used to analyze the functions and pathway enrichment of DEGs. Finally, qRT-PCR and Western blotting were used to verify the genes screened by RNA-Seq analyses. RESULTS: Cell experiments showed that HE-D can inhibit the migration of RAW264.7 macrophages induced by LPS. DEseq2 analyses showed that there were 363 DEGs after HE-D administration in the result of RNA-Seq. The GO function of DEGs was significantly enriched in cell migration and inflammation, and the DEGs related to cell migration were significantly enriched in the NF-κB signaling pathway. qRT-PCR and Western blot analyses, showed that when compared with the LPS group, the related genes IKKα, IKKγ, TRAF6, TLR4, and TRAF5 in the NF-κB pathway were significantly down-regulated in the HE-D group. In addition, it was found that the inflammatory factors iNOS and TNF-α were significantly down-regulated, and Arg-1 and IL-10 were up-regulated. CONCLUSION: HE-D can inhibit the migration of macrophages by inhibiting IKKα and IKKγ in the NF-κB signaling pathway, and promote the transformation of macrophages from M1to M2 subtypes. Therefore, HE-D can potentially be used as a drug for the treatment of atherosclerosis.
Assuntos
Aterosclerose , Sanguessugas , Animais , Aterosclerose/tratamento farmacológico , Aterosclerose/genética , Aterosclerose/metabolismo , Humanos , Quinase I-kappa B/metabolismo , Lipopolissacarídeos/metabolismo , Lipopolissacarídeos/farmacologia , Macrófagos , NF-kappa B/metabolismo , Peptídeos/farmacologia , TranscriptomaRESUMO
In recent years, various viral diseases have suddenly erupted, resulting in widespread infection and death. A variety of biological activities from marine natural products have gradually attracted the attention of people. Seaweeds have a wide range of sources, huge output, and high economic benefits. This is very promising in the pharmaceutical industry. In particular, sulfated polysaccharides derived from seaweeds, considered a potential source of bioactive compounds for drug development, have shown antiviral activity against a broad spectrum of viruses, mainly including common DNA viruses and RNA viruses. In addition, sulfated polysaccharides can also improve the body's immunity. This review focuses on recent advances in antiviral research on the sulfated polysaccharides from seaweeds, including carrageenan, galactan, fucoidan, alginate, ulvan, p-KG03, naviculan, and calcium spirulan. We hope that this review will provide new ideas for the development of COVID-19 therapeutics and vaccines.
RESUMO
Polymannuronic acid (PM) possesses more pharmacological activities than sodium alginate, but there have been few studies on its absorption mechanism, tissue distribution, and pharmacokinetics. Studies of pharmacokinetics and tissue distribution are necessary to elucidate the pharmacological effects of PM. Thus, we used fluorescein isothiocyanate (FITC) to produce fluorescently labeled PM (FITC-PM) and detected the distribution and pharmacokinetics of PM in vivo via tail vein injection. The results demonstrate that the FITC-PM showed high stability in different pH solutions. After the tail vein injection, FITC-PM tended to be distributed in the kidney, followed by the liver and in the heart, spleen, and lungs at lower concentrations. Pharmacokinetic analysis showed that the elimination rate constant of FITC-PM was 0.24, the half-life time was 2.85 h, the peak concentration was 235.17 µg/mL, the area under the curve was 631.48 µg/mL·h, the area under the curve by statistical moment was 1843.15 µg/mL·h2, the mean residence time was 2.92 h, and the clearance rate was 79.18 mL/h. These results indicate that FITC-PM could be used for PM distribution and pharmacokinetic studies, and the studies of pharmacokinetics and tissue distribution provided basic information that can be used to further clarify PM pharmacodynamic mechanisms.
Assuntos
Ácido Algínico , Cauda , Animais , Fluoresceína-5-Isotiocianato , Injeções Intravenosas , Camundongos , Distribuição TecidualRESUMO
Fucoidan is a marine polysaccharide. In recent years, fucoidan has attracted wide-scale attention from the pharmaceutical industries due to its diverse biological activities such as lipid-lowering, anti-atherosclerosis, and anticoagulation. This review clarifies the pharmacological effects of fucoidan in the treatment of human cardiovascular and cerebrovascular diseases. Fucoidan exerts a hypolipidemic effect by increasing the reverse transport of cholesterol, inhibiting lipid synthesis, reducing lipid accumulation, and increasing lipid metabolism. Inflammation, anti-oxidation, and so on have a regulatory effect in the process of atherosclerosis endothelial cells, macrophages, smooth muscle cells, and so on; fucoidan can not only prevent thrombosis through anticoagulation and regulate platelet activation, but also promote the dissolution of formed thrombi. Fucoidan has a neuroprotective effect, and also has a positive effect on the prognosis of the cardiovascular and cerebrovascular. The prospects of applying fucoidan in cardio-cerebrovascular diseases are reviewed to provide some theoretical bases and inspirations for its full-scale development and utilization.
RESUMO
The Caco-2 model is a common cell model for material intestinal absorption in vitro, which usually takes 21 days to establish. Although some studies have shown that adding puromycin (PM) can shorten the model establishment period to 7 days, this still requires a long modeling time. Therefore, exploring a shorter modeling method can reduce the experimental costs and promote the development and application of the model. Fucoidan is an acidic polysaccharide with various biological activities. Our study showed that the transepithelial electrical resistance (TEER) value could reach 600 Ω·cm2 on the fourth day after the addition of fucoidan and puromycin, which met the applicable standards of the model (>500 Ω). Moreover, the alkaline phosphatase (AKP) activity, fluorescein sodium transmittance, and cell morphology of this model all met the requirements of model establishment. Fucoidan did not affect the absorption of macromolecular proteins and drugs. The results indicate that fucoidan can be applied to establish the Caco-2 model and can shorten the model establishment period to 5 days.
RESUMO
Recently, fucoidan has been proposed for use as a potential anti-inflammatory drug. The purpose of this study was to investigate the mechanism of fucoidan in the treatment of ulcerative colitis. We compared the anti-inflammatory effects of fucoidan and fucose induced by dextran sulfate sodium, and the effects of fucoidan and fucose on the gut microbiota of mice. Our results showed that low-dose fucoidan significantly improved weight loss, disease activity index scores, colonic shortening, colonic histopathological damage, intestinal fatty acid binding protein 2 levels, and the expression of Occludin, Claudin-4, and Claudin-1. However, both high-dose fucoidan and fucose did not perform as well as low-dose fucoidan as described above. In addition, 16S rDNA high-throughput sequencing showed that low-dose fucoidan significantly increased the abundance of Alloprevotella, and fucose significantly increased Ruminococcaceae, but neither significantly reversed the imbalance in the gut microbiota. Therefore, we inferred that the regulation of fucoidan on colitis has a unique and complex mechanism, and it is not completely dependent on degradation to fucose to relieve ulcerative colitis, nor is it achieved only by regulating the gut microbiota. The mechanism by which fucoidan treats colitis may also include reducing inflammatory cell infiltration and increasing intestinal barrier function.
RESUMO
Tumors meet their energy, biosynthesis, and redox demands through metabolic reprogramming. This metabolic abnormality results in elevated levels of metabolites, particularly lactate, in the tumor microenvironment. Immune cell reprogramming and cellular plasticity mediated by lactate and lactylation increase immunosuppression in the tumor microenvironment and are emerging as key factors in regulating tumor development, metastasis, and the effectiveness of immunotherapies such as immune checkpoint inhibitors. Reprogramming of glucose metabolism and the "Warburg effect" in hepatocellular carcinoma (HCC) lead to the massive production and accumulation of lactate, so lactate modification in tumor tissue is likely to be abnormal as well. This article reviews the immune regulation of abnormal lactate metabolism and lactate modification in hepatocellular carcinoma and the therapeutic strategy of targeting lactate-immunotherapy, which will help to better guide the medication and treatment of patients with hepatocellular carcinoma.
RESUMO
Atherosclerotic cardiovascular disease became one of the major causes of morbidity and mortality worldwide. As a sulfated polysaccharide with anti-inflammatory and hypolipidemic activities, fucoidan can induce autophagy. We show here that fucoidan reduces lipid accumulation in foam cells, which is one of the causes of atherosclerosis. Further studies show that fucoidan promotes autophagy showed by the expression of p62/SQSTM1 and microtubule-associated protein light chain 3 (LC3) II, which can be blocked by autophagy inhibitors 3-MA and bafilomycin A1. In addition, the expression of transcription factor EB (TFEB), master regulator of autophagy and lysosome function, is upregulated after the treatment with fucoidan. Moreover, the knockout of TFEB with small interfering RNA suppressed the effect of fucoidan. Together, fucoidan reduces lipid accumulation in foam cells by enhancing autophagy through the upregulation of TFEB. In view of the role of foam cells in atherosclerosis, fucoidan can be valuable for the treatment of atherosclerosis.
Assuntos
Autofagia/efeitos dos fármacos , Fatores de Transcrição de Zíper de Leucina e Hélice-Alça-Hélix Básicos/metabolismo , Células Espumosas/efeitos dos fármacos , Metabolismo dos Lipídeos/efeitos dos fármacos , Polissacarídeos/farmacologia , Adenina/análogos & derivados , Adenina/farmacologia , Animais , Sobrevivência Celular/efeitos dos fármacos , Lipoproteínas LDL/farmacologia , Macrolídeos/farmacologia , Camundongos , Células RAW 264.7RESUMO
Fucoxanthin is a natural carotenoid derived mostly from many species of marine brown algae. It is characterized by small molecular weight, is chemically active, can be easily oxidized, and has diverse biological activities, thus protecting cell components from ROS. Fucoxanthin inhibits the proliferation of a variety of cancer cells, promotes weight loss, acts as an antioxidant and anti-inflammatory agent, interacts with the intestinal flora to protect intestinal health, prevents organ fibrosis, and exerts a multitude of other beneficial effects. Thus, fucoxanthin has a wide range of applications and broad prospects. This review focuses primarily on the latest progress in research on its pharmacological activity and underlying mechanisms.
Assuntos
Anti-Inflamatórios/farmacologia , Fármacos Antiobesidade/farmacologia , Antineoplásicos/farmacologia , Antioxidantes/farmacologia , Phaeophyceae , Xantofilas/farmacologia , Animais , Anti-Inflamatórios/isolamento & purificação , Fármacos Antiobesidade/isolamento & purificação , Antineoplásicos/isolamento & purificação , Antioxidantes/isolamento & purificação , Estabilidade de Medicamentos , Microbioma Gastrointestinal/efeitos dos fármacos , Humanos , Phaeophyceae/metabolismo , Xantofilas/isolamento & purificaçãoRESUMO
Atherosclerosis is a chronic disease characterized by lipid accumulation and chronic inflammation of the arterial wall, which is the pathological basis for coronary heart disease, cerebrovascular disease and thromboembolic disease. Currently, there is a lack of low-cost therapeutic agents that effectively slow the progression of atherosclerosis. Therefore, the development of new drugs is urgently needed. The research and development of marine-derived drugs have gained increasing interest from researchers across the world. Many marine organisms provide a rich material basis for the development of atherosclerotic drugs. This review focuses on the latest technological advances in the structures and mechanisms of action of marine-derived anti-atherosclerotic substances and the challenges of the application of these substances including marine polysaccharides, proteins and peptides, polyunsaturated fatty acids and small molecule compounds. Here, we describe the theoretical basis of marine biological resources in the treatment of atherosclerosis.
Assuntos
Organismos Aquáticos/química , Aterosclerose/tratamento farmacológico , Fármacos Cardiovasculares/farmacologia , Ácidos Graxos Insaturados/farmacologia , Polissacarídeos/farmacologia , Proteínas/farmacologia , Animais , Aterosclerose/metabolismo , Aterosclerose/patologia , Fármacos Cardiovasculares/química , Fármacos Cardiovasculares/isolamento & purificação , Ácidos Graxos Insaturados/química , Ácidos Graxos Insaturados/isolamento & purificação , Humanos , Estrutura Molecular , Polissacarídeos/química , Polissacarídeos/isolamento & purificação , Proteínas/química , Proteínas/isolamento & purificação , Relação Estrutura-AtividadeRESUMO
With twice the number of cancer's deaths, cardiovascular diseases have become the leading cause of death worldwide. Atherosclerosis, in particular, is a progressive, chronic inflammatory cardiovascular disease caused by persistent damage to blood vessels due to elevated cholesterol levels and hyperlipidemia. This condition is characterized by an increase in serum cholesterol, triglycerides, and low-density lipoprotein, and a decrease in high-density lipoprotein. Although existing therapies with hypolipidemic effects can improve the living standards of patients with cardiovascular diseases, the drugs currently used in clinical practice have certain side effects, which insists on the need for the development of new types of drugs with lipid-lowering effects. Some marine-derived substances have proven hypolipidemic activities with fewer side effects and stand as a good alternative for drug development. Recently, there have been thousands of studies on substances with lipid-lowering properties of marine origin, and some are already implemented in clinical practice. Here, we summarize the active components of marine-derived products having a hypolipidemic effect. These active constituents according to their source are divided into algal, animal, plant and microbial and contribute to the development and utilization of marine medicinal products with hypolipidemic effects.
Assuntos
Organismos Aquáticos/metabolismo , Aterosclerose/tratamento farmacológico , Dislipidemias/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Metabolismo dos Lipídeos/efeitos dos fármacos , Animais , Aterosclerose/sangue , Aterosclerose/patologia , Dislipidemias/sangue , Humanos , Hipolipemiantes/química , Hipolipemiantes/isolamento & purificação , Lipídeos/sangue , Estrutura Molecular , Placa Aterosclerótica , Metabolismo SecundárioRESUMO
Fucoidan has a variety of pharmacological activities, but the understanding of the mechanism of fucoidan-induced apoptosis of colorectal cancer cells remains limited. The results of the present study demonstrated that the JNK signaling pathway is involved in the activation of apoptosis in colorectal cancer-derived HT-29 cells, and fucoidan induces apoptosis by activation of the DR4 at the transcriptional and protein levels. The survival rate of HT-29 cells was approximately 40% in the presence of 800 µg/mL of fucoidan, but was increased to 70% after DR4 was silenced by siRNA. Additionally, fucoidan has been shown to reduce the mitochondrial membrane potential and destroy the integrity of mitochondrial membrane. In the presence of an inhibitor of cytochrome C inhibitor and DR4 siRNA or the presence of cytochrome C inhibitor only, the cell survival rate was significantly higher than when cells were treated with DR4 siRNA only. These data indicate that both the DR4 and the mitochondrial pathways contribute to fucoidan-induced apoptosis of HT-29 cells, and the extrinsic pathway is upstream of the intrinsic pathway. In conclusion, the current work identified the mechanism of fucoidan-induced apoptosis and provided a novel theoretical basis for the future development of clinical applications of fucoidan as a drug.
Assuntos
Apoptose/efeitos dos fármacos , Mitocôndrias/efeitos dos fármacos , Polissacarídeos/farmacologia , Receptores do Ligante Indutor de Apoptose Relacionado a TNF/metabolismo , Proteínas Reguladoras de Apoptose/metabolismo , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Movimento Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Citocromos c/antagonistas & inibidores , Citocromos c/metabolismo , Células HT29/efeitos dos fármacos , Humanos , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Phaeophyceae/química , Polissacarídeos/química , Polissacarídeos/toxicidade , Transdução de SinaisRESUMO
Alginate is a natural polysaccharide present in various marine brown seaweeds. Alginate oligosaccharide (AOS) is a degradation product of alginate, which has received increasing attention due to its low molecular weight and promising biological activity. The wide-ranging biological activity of AOS is closely related to the diversity of their structures. AOS with a specific structure and distinct applications can be obtained by different methods of alginate degradation. This review focuses on recent advances in the biological activity of alginate and its derivatives, including their anti-tumor, anti-oxidative, immunoregulatory, anti-inflammatory, neuroprotective, antibacterial, hypolipidemic, antihypertensive, and hypoglycemic properties, as well as the ability to suppress obesity and promote cell proliferation and regulate plant growth. We hope that this review will provide theoretical basis and inspiration for the high-value research developments and utilization of AOS-related products.
Assuntos
Alginatos/química , Oligossacarídeos/química , Alga Marinha , Animais , Oceanos e Mares , Relação Estrutura-AtividadeRESUMO
Fucoidan exhibits several pharmacological activities and is characterized by high safety and the absence of toxic side effects. However, the absorption of fucoidan is not well-characterized. In the present study, fucoidan were labeled with fluorescein isothiocyanate (FITC) and their ability to traverse a monolayer of Caco-2 cells was examined. The apparent permeability coefficients (Papp × 10-6) of FITC-labeled fucoidan (FITC-fucoidan) were 26.23, 20.15, 17.93, 16.11 cm/sec, respectively, at the concentration of 10 µg/mL at 0.5, 1, 1.5 and 2 h. The absorption of FITC-fucoidan was suppressed by inhibitors of clathrin-mediated endocytosis, chlorpromazine, NH4Cl, and Dynasore; the inhibition rates were 84.24%, 74.61%, and 63.94%, respectively. This finding suggested that clathrin-mediated endocytosis was involved in fucoidan transport. Finally, tissue distribution of FITC-fucoidan was studied in vivo after injection of 50 mg/kg body weight into the tail vein of mice. The results showed that FITC-fucoidan targeted kidney and liver, reaching concentrations of 1092.31 and 284.27 µg/g respectively after 0.5 h. In summary, the present work identified the mechanism of absorption of fucoidan and documented its tissue distribution, providing a theoretical basis for the future development of fucoidan applications.
Assuntos
Endocitose , Células Epiteliais/metabolismo , Rim/metabolismo , Fígado/metabolismo , Polissacarídeos , Animais , Transporte Biológico , Células CACO-2 , Células Epiteliais/citologia , Fluoresceína-5-Isotiocianato/química , Humanos , Rim/citologia , Fígado/citologia , Camundongos , Polissacarídeos/química , Polissacarídeos/farmacocinética , Polissacarídeos/farmacologia , Distribuição TecidualRESUMO
This is a new expanded method of determining the characterisation of fucoidan from Laminaria japonica (kelp) in rat plasma by high-performance liquid chromatography (HPLC) with fluorescence detection. We tagged fucoidan by fluoresce in isothiocyanate (FITC) for tracking and treated the plasma samples via protein precipitation with 10% trichloroacetic acid and methanol. Column chromatography separation was on a TSK-G4000sw column (7.8 mm × 300 mm, 5 mm) by elution with 0.15 M NaCl. The quantification of fucoidan was performed by HPLC with fluorescence detection. The results suggested that the calibration curve for fucoidan concentration was linear dependent in the limits of 0.5-100µg/mL. The lower limit of quantitation (LLOQ) was 0.5µg/mL and the lower limit of detection (LLOD) was 0.15µg/mL. The intra-day and inter-day precision values were less than 13%and the accuracy ranged from 96.83 to 100.03% at 3 different concentrations. The fucoidan stability of rat plasma at different temperatures and time-points was estimated. The extraction efficiencies ranged from 93.33 to 96.53%and the matrix effect ranged from 92.67 to 95.83%. Method selectivity was evaluated as well. We successfully studied the pharmacokinetic of fucoidan in rat plasma after oral by the validated method. Fucoidan was administered to rats intravenously at a dose of 6 mg/kg and orally at a dose of 20 mg/kg. The Cmax was 7.33µg/mL within 2 h by oral administration; The initial Cmax was 75.59µg/mL. The bioavailability of fucoidan after oral administration to rats was 8.91%.